US · MDT · MEDICAL - DEVICES
Medtronic plc (MDT) intrinsic value and stock valuation
$99.94as of 2026-11-21 · Mkt cap 110.07B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Medtronic plc DCF and intrinsic value
InvestorsCraft values MDT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MDT’s statements →
Medtronic plc Graham Number
Graham Number: $57.37d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2012–2026, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Bristol-Myers Squibb Company (BMY) $58.80
- Stryker Corporation (SYK) $310.00
- CVS Health Corp. (CVS) $80.84
- Vertex Pharmaceuticals Incorporated (VRTX) $515.02
- GSK plc (GSK) $47.76
- McKesson Corporation (MCK) $1,069.43
- Sanofi (SNY) $46.52
- HCA Healthcare, Inc. (HCA) $475.57
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $36.4B | $33.5B | $32.4B | $31.2B | $31.7B |
| Operating income | $6.47B | $5.96B | $5.14B | $5.49B | $5.75B |
| Net income | $4.8B | $4.66B | $3.68B | $3.76B | $5.04B |
| EPSd | $3.73M | $3.61M | $2.76M | $2.82M | $3.73M |
| Operating cash flow | $7.33B | $7.04B | $6.79B | $6.04B | $7.35B |
| Capital expenditure | -$-1.9B | -$-1.86B | -$-1.59B | -$-1.46B | -$-1.37B |
| Free cash flow | $5.43B | $5.19B | $5.2B | $4.58B | $5.98B |
| Total assets | $93B | $91.7B | $90B | $90.9B | $91B |
| Total debt | $28B | $28.5B | $25B | $24.4B | $24.1B |
| Net debt | $26B | $26.3B | $23.7B | $22.8B | $20.4B |
| Total equity | $50.1B | $48.3B | $50.4B | $51.7B | $52.7B |
| Cash and short-term investments | $9.22B | $8.97B | $8.01B | $7.96B | $10.6B |
Income statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $36.4B | $33.5B | $32.4B | $31.2B | $31.7B |
| Cost of revenue | $12.7B | $11.6B | $11.2B | $10.7B | $10.1B |
| Gross profit | $23.6B | $21.9B | $21.1B | $20.5B | $21.5B |
| Research and development expenses | $2.87B | $2.73B | $2.74B | $2.7B | $2.75B |
| Selling, general and administrative expenses | $11.8B | $10.8B | $10.7B | $10.4B | $10.3B |
| Other expenses | $2.52B | $2.37B | $2.53B | $1.91B | $2.75B |
| Operating expenses | $17.2B | $16B | $16B | $15B | $15.8B |
| Cost and expenses | $29.9B | $27.6B | $27.2B | $25.7B | $25.9B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $715M | $729M | $719M | $636M | $553M |
| Depreciation and amortization | $2.96B | $2.86B | $2.65B | $2.7B | $2.71B |
| Ebitda | $9.81B | $9.22B | $8.2B | $8.7B | $8.78B |
| Operating income | $6.47B | $5.96B | $5.14B | $5.49B | $5.75B |
| Total other income/expenses, net | -$-331M | -$-327M | -$-307M | -$-121M | -$-235M |
| Income before tax | $6.14B | $5.63B | $4.84B | $5.36B | $5.52B |
| Income tax expense | $1.3B | $936M | $1.13B | $1.58B | $456M |
| Net income | $4.8B | $4.66B | $3.68B | $3.76B | $5.04B |
| Weighted average shares outstanding | $1.28B | $1.29B | $1.33B | $1.33B | $1.34B |
| Weighted average diluted shares outstanding | $1.29B | $1.29B | $1.33B | $1.33B | $1.35B |
Balance sheet
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $9.22B | $8.97B | $8.01B | $7.96B | $10.6B |
| Net receivables | $6.64B | $6.52B | $6.13B | $6B | $5.55B |
| Inventory | $5.95B | $5.48B | $5.22B | $5.29B | $4.62B |
| Total current assets | $24.8B | $23.8B | $21.9B | $21.7B | $23.1B |
| Property, plant and equipment, net | $7.42B | $6.84B | $6.13B | $5.57B | $5.41B |
| Goodwill and intangible assets | $52.7B | $53.4B | $54.2B | $56.3B | $56.1B |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $68.2B | $67.9B | $68B | $69.3B | $67.9B |
| Total assets | $93B | $91.7B | $90B | $90.9B | $91B |
| Accounts payable | $2.64B | $2.45B | $2.41B | $2.66B | $2.28B |
| Short-term debt | $1.79B | $2.87B | $1.09B | $20M | $3.74B |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $11.7B | $12.9B | $10.8B | $9.05B | $12.4B |
| Long-term debt | $26.2B | $25.6B | $23.9B | $24.3B | $20.4B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $31.3B | $30.5B | $28.8B | $30.2B | $25.9B |
| Capital lease obligations | $60M | $58M | $61M | $64M | $62M |
| Total liabilities | $43B | $43.4B | $39.6B | $39.3B | $38.3B |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | $32.6B | $31.5B | $30.4B | $30.4B | $30.3B |
| Accumulated other comprehensive income (loss) | -$-4.1B | -$-4.28B | -$-3.32B | -$-3.5B | -$-2.27B |
| Total equity | $50.1B | $48.3B | $50.4B | $51.7B | $52.7B |
| Total investments | $7.27B | $6.75B | $6.72B | $6.42B | $6.86B |
| Total debt | $28B | $28.5B | $25B | $24.4B | $24.1B |
| Net debt | $26B | $26.3B | $23.7B | $22.8B | $20.4B |
Cash flow statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net income | $4.84B | $4.69B | $3.68B | $3.78B | $5.06B |
| Depreciation and amortization | $2.96B | $2.86B | $2.65B | $2.7B | $2.71B |
| Stock-based compensation | $457M | $429M | $393M | $355M | $359M |
| Change in working capital | -$-1.42B | -$-1.05B | -$-484M | -$-967M | -$-889M |
| Accounts receivable | -$-200M | -$-433M | -$-391M | -$-576M | -$-477M |
| Inventory | -$-404M | -$-292M | -$-139M | -$-939M | -$-560M |
| Accounts payable | $46M | $209M | $391M | $696M | $213M |
| Net cash provided by operating activities | $7.33B | $7.04B | $6.79B | $6.04B | $7.35B |
| Investments in property, plant and equipment | -$-1.9B | -$-1.86B | -$-1.59B | -$-1.46B | -$-1.37B |
| Acquisitions, net | -$-406M | -$-98M | -$-211M | -$-1.87B | -$-91M |
| Net cash used for investing activities | -$-2.93B | -$-1.94B | -$-2.37B | -$-3.49B | -$-1.66B |
| Common stock issued | $516M | $508M | $284M | $308M | $429M |
| Common stock repurchased | -$-1.04B | -$-3.24B | -$-2.14B | -$-645M | -$-2.54B |
| Dividends paid | -$-3.64B | -$-3.59B | -$-3.67B | -$-3.62B | -$-3.38B |
| Net cash used for financing activities | -$-4.75B | -$-4.36B | -$-4.45B | -$-4.96B | -$-5.34B |
| Net change in cash | -$-269M | $934M | -$-259M | -$-2.17B | $121M |
| Cash at end of period | $1.95B | $2.22B | $1.28B | $1.54B | $3.71B |
| Operating cash flow | $7.33B | $7.04B | $6.79B | $6.04B | $7.35B |
| Capital expenditure | -$-1.9B | -$-1.86B | -$-1.59B | -$-1.46B | -$-1.37B |
| Free cash flow | $5.43B | $5.19B | $5.2B | $4.58B | $5.98B |
Line items
Line items
Line items
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- CEO
- Geoffrey Straub Martha
- Employees
- 95K
- Beta
- 0.58
Included in
Explore
Frequently asked questions
What is the intrinsic value of Medtronic plc (MDT)?
InvestorsCraft does not currently publish an intrinsic value for MDT. How the IC value is calculated.
Is MDT undervalued?
InvestorsCraft does not publish an undervaluation signal for MDT at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.